Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiotropium vs Salmeterol/Fluticasone in COPD
NCT00239499Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2003
- Primary completion
- Aug 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tiotropium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Forced Expiratory Volume in 1 second Area Under the Curve 0-12 hours at 6 weeks. Started Sep 2003; status: completed.
02
Drugs
tiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00239499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00239499.